Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicenter Real-World Study

    May 2025 in “ Clinical & Experimental Allergy ”
    Reineke Soegiharto, Esther Van der Wind, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, Esmee van Lindonk, Fatih Demir, Nasser Mohammad Porras, Yoshimi Matsuo, Lea Kiefer, André C. Knulst, Marcus Maurer, Carla Ritchie, Michael Rudenko, Emek Kocatürk, Roberta Fachini Jardim Criado, Stamatios Gregoriou, Tatjana Bobylev, Andreas Kleinheinz, Shunsuke Takahagi, Michihiro Hide, Ana M. Giménez‐Arnau, Andaç Salman, Rabia Öztaş Kara, Bahar Sevimli Dikicier, Martijn B. A. van Doorn, Simon Francis Thomsen, J. M. P. A. van den Reek, Heike Röckmann
    Studysummary This study confirmed omalizumab's safety but noted that hair loss was more prevalent than previously reported, with side effects influencing treatment decisions especially in patients with reduced medication effectiveness.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results